NCT06349473
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Phase: Phase 1
Role: Lead Sponsor
Start: May 10, 2024
Completion: Apr 27, 2026